Understanding treatment, utilization, and costs in advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC): Implications for episodic payment models.

被引：0
|
作者：
Kelly, Ronan Joseph
Le, Hannah
Wu, Sze-Jung
Laurie, Melissa
Raval, Amit D.
Shi, Qian
Korytowsky, Beata
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Bristol Myers Squibb Co, Lawrenceville, NJ USA
[3] HealthCore, Wilmington, DE USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e16035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16035
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [41] Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
    Moehler, Markus H.
    Kato, Ken
    Arkenau, Hendrik-Tobias
    Oh, Do-Youn
    Tabernero, Josep
    Cruz-Correa, Marcia
    Wang, HongWei
    Xu, Hui
    Li, Jiang
    Yang, Silu
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 286 - 286
  • [42] Nivolumab ± Ipilimumab in patients (pts) with advanced (adv) / metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: checkMate 032 study
    Jaeger, D.
    Janjigian, Y. Y.
    Ott, P. A.
    Calvo, E.
    Kim, J. W.
    Ascierto, P. A.
    Sharma, P.
    Peltola, K.
    Evans, J.
    de Braud, F.
    Chau, I.
    Tschaika, M.
    Harbison, C. T.
    Cai, W.
    Bendell, J.
    Le, D. T.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 209 - 209
  • [43] Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis
    Kang, Y-K.
    Qin, S.
    Lee, K-W.
    Oh, S. C.
    Kim, I-H.
    Kim, J. G.
    Li, Y.
    Yan, Z.
    Li, J.
    Bai, L-Y.
    Chan, C. P. K.
    Yusuf, A.
    Zahlten-Kuemeli, A.
    Taylor, K.
    Yamaguchi, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1525 - S1525
  • [44] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649
    Elimova, Elena
    Shitara, Kohei
    Moehler, Markus H.
    Ajani, Jaffer A.
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Wyrwicz, Lucjan S.
    Yamaguchi, Kensei
    Cleary, James M.
    Maya, Ricardo Elias Bruges
    Karamouzis, Michalis
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshu
    Tehfe, Mustapha
    Feeney, Kynan
    Wang, Rui
    Nathani, Raheel
    Janjigian, Yelena Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Real-world treatment patterns, testing patterns, and clinical outcomes of first-line (1L) therapy for metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (mGC/GEJC/EAC).
    Kakehi, Sumie
    Betts, Keith A.
    Nie, Xiaoyu
    Kitchen, Sophie A.
    Ray, Saurabh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 275 - 275
  • [46] Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649
    Shitara, Kohei
    Janjigian, Yelena Y.
    Moehler, Markus H.
    Garrido, Marcelo
    Gallardo, Carlos
    Shen, Lin
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Skoczylas, Tomasz
    Silva, Arinilda
    Bragagnoli, Campos
    Liu, Tianshu
    Tehfe, Mustapha
    Elimova, Elena
    Soleymani, Samira
    Lei, Ming
    Kondo, Kaoru
    Li, Mingshun
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [47] Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemothera py-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.
    Janjigian, Yelena Yuriy
    Ott, Patrick Alexander
    Calvo, Emiliano
    Kim, Joseph W.
    Ascierto, Paolo Antonio
    Sharma, Padmanee
    Peltola, Katriina Johanna
    Jaeger, Dirk
    Evans, T. R. Jeffry
    De Braud, Filippo G.
    Chau, Ian
    Tschaika, Marina
    Harbison, Christopher T.
    Cai, Weiguo
    Bendel, Johanna C.
    Le, Dung T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
    Moehler, M.
    Janjigian, Y. Y.
    Shitara, K.
    Garrido, M.
    Gallardo, C.
    Shen, L.
    Yamaguchi, K.
    Wyrwicz, L.
    Skoczylas, T.
    Bragagnoli, A.
    Liu, T.
    Tehfe, M.
    Elimova, E.
    Bruges, R.
    Cleary, J. M.
    Karamouzis, M.
    Soleymani, S.
    Lei, M.
    Amaya, Chanaga C.
    Ajani, J. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 114 - 115
  • [49] Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC)
    Moehler, Markus H.
    Dvorkin, Mikhail
    Ozguroglu, Mustafa
    Ryu, Min-hee
    Muntean, Alina Simona
    Lonardi, Sara
    Nechaeva, Marina
    Bragagnoli, Arinilda Silva Campos
    Coskun, Hasan Senol
    Gracian, Antonio Cubillo
    Takano, Toshimi
    Wong, Rachel
    Safran, Howard
    Vaccaro, Gina M.
    Boku, Narikazu
    Conti, Ilaria
    Hong, Janet
    Xiong, Huiling
    Taieb, Julien
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [50] Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction cancer (GC/GEJC): A prospective, multi-center, phase II study
    Jiao, Zuoyi, Sr.
    Zhou, Huinian, Sr.
    Yu, Zyuaun, Sr.
    Long, Bo
    Huang, Zeping
    Zhao, Da
    Wei, Dengwen
    Zhao, Xiaonin
    Jiang, Zebin
    Yang, Xiaojun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345